Superworth

Vor Biopharma VOR

Biotechnology, Healthcare
$19.25
−2.19%
Market cap
$1.2B
PE
n/m
not a meaningful number
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
−10.1%

Charts

Financials

Income statement for VOR, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
R&D$20.9M+23%$24.3M+11%$21.8M−9%$21.8M−21%$25.3M+21%$26.7M+10%$261.5M+1098%$14.1M−35%$19.2M−24%$17.6M−34%$25.9M−90%$34.5M+144%
SG&A$7.2M−6%$8M−6%$7.2M−13%$6.7M−13%$6M−18%$6.6M−18%$12.8M+77%$14M+109%$16.8M+181%$17.6M+167%$21.9M+72%$23.9M+71%
−$28.1M+14%−$32.3M+6%−$29M−10%−$28.5M−19%−$31.3M+11%−$33.3M+3%−$274.3M+845%−$28.1M−1%−$36M+15%−$35.2M+6%−$47.9M−83%−$58.4M+108%
Net income−$26.3M+10%−$30.8M+8%−$27.8M−7%−$27.6M−17%−$30.7M+17%−$32.5M+6%−$1.6B+5553%−$812.7M+2849%$1.7B−$219.6M+576%−$62.8M−96%−$86.7M−89%
−$7.80−26%−$9.00+5%−$8.20−9%−$8.05−18%−$8.77+12%−$5.21−42%−$251.24+2964%−$121.63+1411%$85.36−$5.11−2%−$1.16−100%−$1.45−99%
3.4M+49%3.4M+3%3.4M+2%3.4M+1%3.5M+3%6.2M+84%6.3M+83%6.7M+95%20.2M+477%43M+589%54.3M+767%59.7M+793%

EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 5 periods, Q4 FY20 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Biotechnology nearest Vor Biopharma's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
VORVor Biopharma$1.2Bn/mn/an/mn/mn/m
MGTXMeiraGTx$895.1M13.1×15.4×2.3×n/m19.9%
VCELVericel$2.1B88.1×157×6.8×+23%7.9%
ADMAAdma Biologics$2.5B15.8×21.3×4.8×+8%33.0%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
KRYSKrystal Biotech$8.8B37.1×42.5×19.9×+23%54.8%
RGENRepligen$9.8B237×123×12.4×+16%5.3%
TECHBIO-TECHNE$11.4B63.2×62.0×9.4×−0%15.0%
Peer median$2.5B37.1×42.5×6.8×+20%19.9%

More on Vor Biopharma

Each number over time

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .